Series A · Biotech · Copenhagen, Denmark · Founded 2020 · 10–25 employees
Neumirna Therapeutics is developing RNA-based therapies targeting neurological disorders, specifically focusing on microRNA modulation to address root causes rather than symptoms. The company's lead candidate NMT.001 is a clinical-stage antisense oligonucleotide therapy for drug-resistant epilepsy, with a preclinical Parkinson's disease program. Founded in 2020 by experienced neuroscience leaders including Henrik Klitgaard (discoverer of Levetiracetam/Keppra), the company recently secured €20M in Series A funding and has support from the Michael J. Fox Foundation. Their proprietary platform for targeted intrathecal delivery represents a novel approach to treating previously intractable neurological conditions.
No open roles listed right now.